Su, Yung-Yeh

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., et al. (2024) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 90

P-124 Nivolumab plus ipilimumab as neoadjuvant therapy for potentially resectable hepatocellular carcinoma

Su, Y., Lin, Y., Hsiao, C., Ou, D., Chen, S., Wu, Y., Lee, W., Lin, J., Hsu, C., Ho, M., et al. (2021) · Annals of Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 11